

Hampig Raphael Kourie

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3593834/publications.pdf>

Version: 2024-02-01

109
papers

1,246
citations

471509

17
h-index

454955

30
g-index

111
all docs

111
docs citations

111
times ranked

2733
citing authors

#	ARTICLE	IF	CITATIONS
1	Cancer patients and research during COVID-19 pandemic: A systematic review of current evidence. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 150, 102972.	4.4	178
2	<p>Triple-negative breast cancer: current perspective on the evolving therapeutic landscape</p>. <i>International Journal of Women's Health</i> , 2019, Volume 11, 431-437.	2.6	117
3	Telemedicine for cancer patients during COVID-19 pandemic: between threats and opportunities. <i>Future Oncology</i> , 2020, 16, 1225-1227.	2.4	84
4	New developments in the management of head and neck cancer – impact of pembrolizumab. <i>Therapeutics and Clinical Risk Management</i> , 2018, Volume 14, 295-303.	2.0	55
5	Anal cancer treatment: Current status and future perspectives. <i>World Journal of Gastroenterology</i> , 2015, 21, 2294.	3.3	48
6	Road map for pain management in pancreatic cancer: A review. <i>World Journal of Gastrointestinal Oncology</i> , 2016, 8, 599.	2.0	44
7	Intravitreal bevacizumab for retinal capillary hemangioblastoma: A case series and literature review. <i>Canadian Journal of Ophthalmology</i> , 2014, 49, 450-457.	0.7	34
8	Metastatic gastric cancer treatment: Second line and beyond. <i>World Journal of Gastroenterology</i> , 2016, 22, 3069.	3.3	30
9	The emerging use of immune checkpoint blockade in the adjuvant setting for solid tumors: a review. <i>Immunotherapy</i> , 2019, 11, 1409-1422.	2.0	28
10	Dilemma of first line regimens in metastatic pancreatic adenocarcinoma. <i>World Journal of Gastroenterology</i> , 2016, 22, 10124.	3.3	27
11	The Lebanese Society of Medical Oncology (LSMO) statement on the care of patients with cancer during the COVID-19 pandemic. <i>Future Oncology</i> , 2020, 16, 615-617.	2.4	27
12	Where does chemotherapy stands in the treatment of ampullary carcinoma? A review of literature. <i>World Journal of Gastrointestinal Oncology</i> , 2016, 8, 745.	2.0	21
13	Immunotherapy: last bullet in platinum refractory germ cell testicular cancer. <i>Future Oncology</i> , 2019, 15, 533-541.	2.4	21
14	The psychological challenges for oncological patients in times of COVID-19 pandemic: telemedicine, a solution?. <i>Future Oncology</i> , 2020, 16, 2265-2268.	2.4	21
15	Optimum chemotherapy in the management of metastatic pancreatic cancer. <i>World Journal of Gastroenterology</i> , 2014, 20, 2352.	3.3	19
16	The second wave of immune checkpoint inhibitor tsunamis: advance, challenges and perspectives. <i>Immunotherapy</i> , 2017, 9, 647-657.	2.0	19
17	Adding checkpoint inhibitors to tyrosine kinase inhibitors targeting EGFR/ALK in non-small cell lung cancer: a new therapeutic strategy. <i>Investigational New Drugs</i> , 2016, 34, 794-796.	2.6	17
18	Adenoid cystic carcinoma of the breast â€“ an aggressive presentation with pulmonary, kidney, and brain metastases: a case report. <i>Journal of Medical Case Reports</i> , 2017, 11, 303.	0.8	17

#	ARTICLE	IF	CITATIONS
19	Do immune-related adverse events correlate with response to immune checkpoint inhibitors?. Immunotherapy, 2019, 11, 257-259.	2.0	17
20	PARP inhibitors: a tsunami of indications in different malignancies. Pharmacogenomics, 2020, 21, 221-230.	1.3	16
21	PD-L1 expression as a predictive biomarker for immune checkpoint inhibitors: between a dream and a nightmare. Immunotherapy, 2021, 13, 1053-1065.	2.0	16
22	EGFR mutation status in Middle Eastern patients with non-squamous non-small cell lung carcinoma: A single institution experience. Cancer Epidemiology, 2015, 39, 1099-1102.	1.9	15
23	Exploring the knowledge gap of immune checkpoint inhibitors in chronic renal failure: A systematic review of the literature. Critical Reviews in Oncology/Hematology, 2021, 157, 103169.	4.4	14
24	Ocular and orbital side effects of ALK inhibitors: a review article. Future Oncology, 2019, 15, 1939-1945.	2.4	13
25	Targeted therapies in urothelial bladder cancer: a disappointing past preceding a bright future?. Future Oncology, 2019, 15, 1505-1524.	2.4	12
26	Acute myeloid leukemia transformed to a targetable disease. Future Oncology, 2020, 16, 961-972.	2.4	12
27	The impact of the coronavirus pandemic on the management of cancer patients in Lebanon: a single institutional experience. Future Oncology, 2020, 16, 1157-1160.	2.4	12
28	Emerging treatments for HER2-positive early-stage breast cancer: focus on neratinib. OncoTargets and Therapy, 2017, Volume 10, 3363-3372.	2.0	11
29	The future of cancer research after COVID-19 pandemic: recession?. Future Oncology, 2020, 16, 1493-1495.	2.4	11
30	YouTube as a source of information on breast cancer in the Arab world. Supportive Care in Cancer, 2021, 29, 8009-8017.	2.2	11
31	Treating cancer patients in times of COVID-19 pandemic: A virtual women cancers multidisciplinary meeting experience. Bulletin Du Cancer, 2020, 107, 738-740.	1.6	10
32	Optimum chemotherapy for the management of advanced biliary tract cancer. World Journal of Gastroenterology, 2015, 21, 4121.	3.3	10
33	Immunotherapies in sarcoma: Updates and future perspectives. World Journal of Clinical Oncology, 2017, 8, 145.	2.3	10
34	Osteonecrosis of the jaw during biyearly treatment with zoledronic acid for aromatase inhibitor associated bone loss in early breast cancer: A literature review. Journal of Bone Oncology, 2015, 4, 77-79.	2.4	9
35	Electronic patient-reported outcomes: a revolutionary strategy in cancer care. Future Oncology, 2017, 13, 2397-2399.	2.4	9
36	Is it possible to rechallenge with PD-1/PD-L1 inhibitors after progression?. Immunotherapy, 2018, 10, 345-347.	2.0	9

#	ARTICLE	IF	CITATIONS
37	Do immune checkpoint inhibitors increase sensitivity to salvage chemotherapy?. <i>Immunotherapy</i> , 2018, 10, 163-165.	2.0	9
38	PD-L1: an unavoidable biomarker in advanced triple-negative breast cancer. <i>Biomarkers in Medicine</i> , 2019, 13, 1539-1541.	1.4	9
39	Checkpoint inhibitors in gastrointestinal cancers: Expectations and reality. <i>World Journal of Gastroenterology</i> , 2017, 23, 3017.	3.3	9
40	Digestive Neuroendocrine Tumor Distribution and Characteristics According to the 2010 WHO Classification: a Single Institution Experience in Lebanon. <i>Asian Pacific Journal of Cancer Prevention</i> , 2016, 17, 2679-81.	1.2	9
41	Bladder cancer knowledge in the Lebanese population: When ignorance could be harmful. <i>Bulletin Du Cancer</i> , 2018, 105, 857-861.	1.6	8
42	Is metastatic pancreatic cancer an untargetable malignancy?. <i>World Journal of Gastrointestinal Oncology</i> , 2016, 8, 297.	2.0	8
43	Diagnosis and treatment of lymphomas in the era of epigenetics. <i>Blood Reviews</i> , 2021, 48, 100782.	5.7	7
44	KRAS-G12C covalent inhibitors: A game changer in the scene of cancer therapies. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 168, 103524.	4.4	7
45	The combination of immune checkpoint inhibitors and chemotherapy in advanced non-small-cell lung cancer: the rational choice. <i>Immunotherapy</i> , 2022, 14, 155-167.	2.0	7
46	Polygenic and Network-based studies in risk identification and demystification of cancer. <i>Expert Review of Molecular Diagnostics</i> , 2022, 22, 427-438.	3.1	7
47	Complete Disappearance of Choroidal Metastasis from Lung Adenocarcinoma Treated with Bevacizumab and Chemotherapy. <i>Case Reports in Ophthalmological Medicine</i> , 2015, 2015, 1-4.	0.5	6
48	Physical long-term side-effects in young adult cancer survivors: germ cell tumors model. <i>Current Opinion in Oncology</i> , 2017, 29, 229-234.	2.4	6
49	The merit of tyrosine kinase inhibitors in the adjuvant setting of high-risk renal cell carcinoma: a meta-analysis. <i>Future Oncology</i> , 2018, 14, 829-835.	2.4	6
50	Molecular profiling of basal cell carcinomas in young patients. <i>BMC Medical Genomics</i> , 2021, 14, 187.	1.5	6
51	Knowledge, Practice, and Attitudes of Physicians in Low- and Middle-Income Countries on Fertility and Pregnancy-Related Issues in Young Women With Breast Cancer. <i>JCO Global Oncology</i> , 2022, 8, e2100153.	1.8	6
52	Is gut microbiome a predictive marker to response to immune checkpoint inhibitors?. <i>Immunotherapy</i> , 2017, 9, 865-866.	2.0	5
53	TRK inhibitors: toward an era of agnostic targeted therapies in oncology. <i>Pharmacogenomics</i> , 2019, 20, 927-929.	1.3	5
54	Finally, after decades, immune checkpoint inhibitors dethroned the standard of care of small-cell lung cancer. <i>Immunotherapy</i> , 2019, 11, 457-460.	2.0	5

#	ARTICLE	IF	CITATIONS
55	Poly-(ADP-ribose) polymerase inhibitors: paradigm shift in the first-line treatment of newly diagnosed advanced ovarian cancer. <i>Pharmacogenomics</i> , 2020, 21, 721-727.	1.3	5
56	KRAS-targeted therapies in advanced solid cancers: drug the undruggable?. <i>Pharmacogenomics</i> , 2021, 22, 587-590.	1.3	5
57	Urothelial carcinoma in the era of immune checkpoint inhibitors. <i>Immunotherapy</i> , 2021, 13, 953-964.	2.0	5
58	Gastrointestinal cancers in the era of theranostics: Updates and future perspectives. <i>World Journal of Gastroenterology</i> , 2015, 21, 8473.	3.3	5
59	Charcot-Marie-Tooth hereditary neuropathy revealed after administration of docetaxel in advanced breast cancer. <i>World Journal of Clinical Oncology</i> , 2017, 8, 425-428.	2.3	5
60	Successful Eltrombopag treatment of refractory idiopathic thrombocytopenic purpura associated with Crohn disease. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2015, 39, e23-e24.	1.5	4
61	Untreated chronic lymphocytic leukemia in Lebanese patients: an observational study using standard karyotyping and FISH. <i>International Journal of Hematologic Oncology</i> , 2017, 6, 105-111.	1.6	4
62	Prognostic and predictive biomarkers in nonmetastatic colorectal cancers. <i>Future Oncology</i> , 2018, 14, 2097-2102.	2.4	4
63	Urging medical students to publish: Advantages, disadvantages and new challenges. <i>Bulletin Du Cancer</i> , 2018, 105, 626-628.	1.6	4
64	Managing Hodgkin lymphoma without chemotherapy: a novel, yet "welcomed" challenge. <i>Future Oncology</i> , 2016, 12, 1435-1437.	2.4	3
65	Negative predictive biomarkers of checkpoint inhibitors in hyper-progressive tumors. <i>Biomarkers in Medicine</i> , 2017, 11, 819-821.	1.4	3
66	Skin adverse events in recently approved targeted therapies in solid malignancies. <i>Future Oncology</i> , 2019, 15, 331-343.	2.4	3
67	The Opinion of Oncologists on the Practice of Hypnosis among Cancer Patients in Lebanon. <i>Complementary Therapies in Medicine</i> , 2020, 53, 102534.	2.7	3
68	Targeting glioblastoma: from dream to reality. <i>Biomarkers in Medicine</i> , 2021, 15, 385-388.	1.4	3
69	Association of prognostic value of primary tumor location in stage III colon cancer with RAS and BRAF mutational status.. <i>Journal of Clinical Oncology</i> , 2017, 35, 3515-3515.	1.6	3
70	BRAFV600 mutant non-small-cell lung cancer resistant to Vemurafenib. <i>International Journal of Clinical and Experimental Pathology</i> , 2015, 8, 3294-8.	0.5	3
71	How and when adjuvant treatment should be intensified in stage III colorectal cancers?. <i>Future Oncology</i> , 2017, 13, 1999-2006.	2.4	2
72	Bioethical considerations for cancer patient care during the COVID-19 pandemic. <i>Future Oncology</i> , 2020, 16, 2779-2781.	2.4	2

#	ARTICLE	IF	CITATIONS
73	Epidemiologic and histologic characteristics of CNS lesions: a 20-year experience of a tertiary center in Lebanon. <i>CNS Oncology</i> , 2020, 9, CNS55.	3.0	2
74	Targeted therapies for cancer during the COVID-19 pandemic: a threat or a blessing?. <i>Pharmacogenomics</i> , 2020, 21, 731-733.	1.3	2
75	Will advanced cholangiocarcinoma become a targetable malignancy?. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 159, 103233.	4.4	2
76	Immunotherapy in neoadjuvant setting in muscle-invasive bladder cancer, whatâ€™s new?. <i>Immunotherapy</i> , 2021, 13, 459-463.	2.0	2
77	Targeting <i>PIK3CA</i> in <i>HER2</i> -positive breast cancer: what are the opportunities and the challenges?. <i>Biomarkers in Medicine</i> , 2021, 15, 609-613.	1.4	2
78	Are there monogenic hereditary forms of bladder cancer or only genetic susceptibilities?. <i>Pharmacogenomics</i> , 2021, 22, 619-628.	1.3	2
79	Molecular pathogenesis of hereditary lung cancer: a literature review. <i>Pharmacogenomics</i> , 2021, 22, 791-803.	1.3	2
80	EGFR mutation incidence and characteristics in non-squamous lung carcinoma in the Lebanese population.. <i>Journal of Clinical Oncology</i> , 2015, 33, e18506-e18506.	1.6	2
81	Histologic Distribution of Pulmonary Tumors in Lebanon: A 5-Year Single Institution Experience. <i>Asian Pacific Journal of Cancer Prevention</i> , 2015, 16, 5899-5902.	1.2	2
82	Does tumor side represent a relevant factor for prognosis and treatment decision in metastatic colorectal cancer?. <i>Colorectal Cancer</i> , 2016, 5, 91-93.	0.8	1
83	Checkpoint inhibitors in the treatment of brain metastases of non-small-cell lung cancer and melanoma. <i>Future Oncology</i> , 2017, 13, 1097-1103.	2.4	1
84	Do checkpoint inhibitors provide new hope for management of metastatic penile carcinoma?. <i>Future Oncology</i> , 2018, 14, 677-680.	2.4	1
85	Seizures in cancer patients: a vast spectrum of etiologies. <i>Future Neurology</i> , 2019, 14, FNL30.	0.5	1
86	Is ramucirumab still the only second-line treatment in metastatic gastric cancer?. <i>Pharmacogenomics</i> , 2020, 21, 1203-1206.	1.3	1
87	A rare case of acute myeloid leukemia with t(12;19)(q13;q13). <i>Leukemia Research Reports</i> , 2020, 14, 100216.	0.4	1
88	Agnostic biomarkers in gastrointestinal tumors: microsatellite instability and NTRK. <i>Personalized Medicine</i> , 2021, 18, 5-7.	1.5	1
89	An unusual case of chronic lymphocytic leukemia with trisomy 12 and t(14;18) and a favorable response to ibrutinib. <i>Leukemia Research Reports</i> , 2021, 15, 100245.	0.4	1
90	Outcome of Breast Cancer Screening: A Lebanese Single Institution Experience. <i>Asian Pacific Journal of Cancer Prevention</i> , 2014, 15, 9471-9473.	1.2	1

#	ARTICLE	IF	CITATIONS
91	Results of NGS panel of hereditary breast and ovarian cancer in Lebanese women.. Journal of Clinical Oncology, 2019, 37, e13045-e13045.	1.6	1
92	Poly(ADP-ribose) polymerase inhibitors in prostate cancer: a cornerstone in precision oncology. Pharmacogenomics, 2021, 22, 1237-1250.	1.3	1
93	HER2 in gastric adenocarcinoma: where do we stand today?. Personalized Medicine, 2022, 19, 67-78.	1.5	1
94	The rapidly evolving landscape of advanced gastric cancer therapy. Future Oncology, 2022, , .	2.4	1
95	Where do immune checkpoint inhibitors stand in the management of thymic epithelial tumors?. Immunotherapy, 2018, 10, 823-826.	2.0	0
96	FOLFIRINOX: a new standard of care in the adjuvant setting of resectable pancreatic adenocarcinomas. Future Oncology, 2019, 15, 1947-1950.	2.4	0
97	Whole-exome and whole-genome sequencing in chronic lymphocytic leukemia: new biomarkers to target. Pharmacogenomics, 2020, 21, 957-962.	1.3	0
98	In reply to: incorporating teleoncology practices in the undergraduate medical curriculum. Future Oncology, 2021, 17, 11-12.	2.4	0
99	Perioperative chemotherapy with modified FOLFIRINOX for nonmetastatic pancreatic cancer: a new standard of care?. Future Oncology, 2021, 17, 229-233.	2.4	0
100	<i>NTRK</i> genes and cancer: when arresting the fusion underlies the treatment. Epigenomics, 2021, 13, 561-564.	2.1	0
101	Rearranged-in-transfection inhibitors: emerging agnostic targeted therapies for solid tumors. Pharmacogenomics, 2021, 22, 247-250.	1.3	0
102	After decades, RAS mutation has finally become a therapeutic target. Personalized Medicine, 2021, 18, 523-525.	1.5	0
103	Efficacy and tolerability of second-line intra-arterial 5FU or mitomycin C after intra-arterial oxaliplatin failure in patients with colorectal cancer and unresectable liver metastases.. Journal of Clinical Oncology, 2017, 35, e15061-e15061.	1.6	0
104	Epidemiologic and histologic characteristics of central nervous system lesions: A 20-year experience of a single institution in Lebanon.. Journal of Clinical Oncology, 2019, 37, e13544-e13544.	1.6	0
105	Immune checkpoint inhibitors in ocular melanomas: contrasting efficacy with cutaneous melanomas. Immunotherapy, 2020, 12, 1149-1152.	2.0	0
106	Pembrolizumab: first adjuvant immunotherapy in renal cell carcinoma?. Future Oncology, 2022, 18, 519-522.	2.4	0
107	Knowledge and behavior of Lebanese parents regarding melanoma prevention in public and private school children. Melanoma Management, 2021, 8, MMT59.	0.5	0
108	BRAF: a biomarker not to be missed in glioblastoma. Personalized Medicine, 2022, 19, 79-82.	1.5	0

#	ARTICLE	IF	CITATIONS
109	Talazoparib in <i>BRCA</i> -mutated advanced breast cancer: is it earlier better?. <i>Pharmacogenomics</i> , 2022, 23, 487-492.	1.3	0